Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. METHODS: In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks. The two primary end points were the percent change in body weight and the percentage of patients with a weight reduction of at least 5%. Additional end points were changes in glycemic measures and safety assessments. Effect estimates were calculated with the use of the treatment-policy estimand (consistent with the intention-to-treat principle). RESULTS: A total of 1206 patients underwent randomization to either the cagrilintide-semaglutide group (904 patients) or the placebo group (302 patients). The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001). More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison). The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group. Gastrointestinal adverse events were reported by 72.5% of the patients in the cagrilintide-semaglutide group and 34.4% in the placebo group, most of which were transient and mild or moderate in severity. CONCLUSIONS: Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes. (Funded by Novo Nordisk; REDEFINE 2 ClinicalTrials.gov number, NCT05394519.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase 3 trial in people with type 2 diabetes, cagrilintide-semaglutide (2•4 mg/week of cagrilintide and semaglutide each) reduced HbA 1c by 1•4% (95% CI 1•2-1•6) or 15 mmol/mol (13-17), and bodyweight by 10•4% (9•5-11•2; placebocorrected).127”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [127]
In the citing paper
“In a phase 3 trial in people with type 2 diabetes, cagrilintide-semaglutide (2•4 mg/week of cagrilintide and semaglutide each) reduced HbA 1c by 1•4% (95% CI 1•2-1•6) or 15 mmol/mol (13-17), and bodyweight by 10•4% (9•5-11•2; placebocorrected).127”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [127]
In the citing paper
“The results from REDEFINE-1 and REDEFINE-2, demonstrated the efficacy of cagrisema, both in obese people with T2DM and those without T2DM [144,145].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [145]
In the citing paper
“Notably, in the latter population, cagrisema induced WL of up to 22.7%, significantly surpassing the effects of either component alone.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [145]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Self-citationGarvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Cited by
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Self-citationNauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Self-citationTuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
Buse, J. B., BAJAJ, H. S., Dalskov, S., Donaldson, L., Duus, H. H. H., Fabricius, T. W., Haluzík, M., Lingvay, I., Pedersen, S. D., Pratley, R. E., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00125-7 · Cited by 22
Self-citationThe story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
Pharmacological therapies for type 2 diabetes: future approaches
Bailey, C. J. (2025) · Diabetologia · doi:10.1007/s00125-025-06581-6 · Cited by 28
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 17
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Rosenstock, J., Billings, L. K., Gajria, R., Giorgino, F., Johansen, N. B., Klein, K. R., Thamattoor, U. K., Buse, J. B., & Jain, A. B. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01022-6 · Cited by 15
Self-citationHoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Another promising direction involves combination therapies – particularly co-administration of GLP-1 RAs with SGLT2 inhibitors or long-acting amylin analogs like cagrilintide – to synergistically enhance weight loss and mitigate weight regain following monotherapy cessation [51,54].”
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies
Rejili, M. S., Hussain, M. S., Khan, Y., Haouala, F., Ganesan, S., Sahoo, S., Pal, A., & Arora, V. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107563 · Cited by 7
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet, M. H. A., Nardone, M., Rensen, P. C. N., Cherney, D. Z. I., & Cooper, M. E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01776-3 · Cited by 11
Patil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
Yamauchi, T., Becker, N., Hagemann, C. A., Huang, K.-C., Kiyosue, A., Lim, S., Onishi, Y., Kosuvaripalli, A., Takano, T., & Ishigaki, Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00402-4 · Cited by 12
Gezginer, I., Mazzini, G., Foll, C. L., Kindler, D., Lutz, T. A., & Razansky, D. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102313 · Cited by 7
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2026) · BMJ · doi:10.1136/bmj-2026-372161 · Cited by 20
Self-citationLi, X., He, C., & Lee, K. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.023 · Cited by 5
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2026) · Peptides · doi:10.1016/j.peptides.2026.171480 · Cited by 7
Ludwig, M. Q., Coester, B., Gordian, D., Hassan, S., Tomlinson, A. J., Toure, M. H., Christensen, O. P., Lommi, G., Moltke-Prehn, A., Brown, J. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01539-3 · Cited by 21
Park, C., Kim, Y., Raygani, S., & Grunvald, E. L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630199 · Cited by 7
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum
Schnell, O., Agarwal, A., Azizi, M., Ballwieser, D. A., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Bugianesi, E., Cebrián, A., Ceriello, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03140-0 · Cited by 6
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity
Sun, X., Brueck, L., Yang, D., Sheets, P. L., Zhou, B., & Ren, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110768 · Cited by 5
Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
Old, V. J., Davies, M. J., Denniff, M. J., Choudhary, P., Eastley, N. C., Ashford, R. U., & Watson, E. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70254 · Cited by 6
Self-citationPharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Heftdal, L. D., Carlander, A. F., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01248-1 · Cited by 5
Self-citationGLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
The year in cardiovascular medicine 2025: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Marx, N., & Cannon, C. P. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1125 · Cited by 2
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Wang, Y., Feng, Z., & Yu, L. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100150 · Cited by 2
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145358 · Cited by 6
What is the role of amylin as an emerging therapeutic agent in obesity?
Bogaerts, G., Lommi, G., & Lutz, T. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2668391 · Cited by 1
Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care
Hales, C. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2509700 · Cited by 1
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Hamarsheh, S., Jaber, A. R., Abu-Khazneh, O., Andonie, C. R., Majadleh, S., Zahran, A., & Ayesh, H. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70248 · Cited by 2
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Martínez‐Castelao, A., Górriz, J. L., Fernández‐Fernández, B., Soler, M. J., & Navarro‐González, J. F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238326 · Cited by 4
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Self-citationde Jesus, F. G., Duque, A. P., Huguenin, G. V. B., Mediano, M. F. F., de Almeida, M. T., Caldas, C. A., Marques-Neto, S. R., & Rodrigues, L. F. (2026) · Healthcare · doi:10.3390/healthcare14081008 · Cited by 1
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.030 · Cited by 4
Al-Harbi, F. A., Alsaif, A. K., Almutairi, A. M., Alshehri, H. J., Aleidan, E. A., Alabdulaaly, G. S., Alanazi, M. E., & Azzam, A. Y. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100414 · Cited by 1
Trends in Diagnosing Obesity: The CALOR Study
Horn, D. B., Lesén, E., Gray, C. M., Bjursell, M. K., & Waki, H. (2026) · Obesity · doi:10.1002/oby.70264 · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Advanced Peptide Modifications for Superior Therapeutics
Bhadra, J., De, N., Momin, M. S. A., Sannigrahi, A., & Bhunia, D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00826 · Cited by 2
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 5
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
Chi, H., Yang, H., & Deng, Y. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2513141 · Cited by 1
Liver–pancreas communication in disease and drug development
Jia, Y., Zhu, Q., Pan, Q., Lu, G., & Xiao, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.018 · Cited by 3
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Vu, Q. L., Chiu, I.-H., Hoang, C. T. H., Bui, N. T. Q., Suhail, M., & Wu, P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119249 · Cited by 1
Structurally defining neurokinin selectivity to improve NK2R agonists
Pavlovskyi, A., Ren, Y., Gestal-Mato, M., Olsen, O. H., Schwartz, T. W., Gerhart‐Hines, Z., & Liu, X. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01820-9 · Cited by 1
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Amylin: A Multi‐Functional Pancreatic Hormone—A Review
Foll, C. L., & Lutz, T. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71146 · Cited by 1
Bruna-Mejías, A., Valenzuela‐Fuenzalida, J. J., Oyanedel-Amaro, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026) · Nutrients · doi:10.3390/nu18111781 · Cited by 3
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
Han, J., Peng, S., Zhang, J., & Huang, X. (2026) · Pharmacoeconomics and Policy · doi:10.2139/ssrn.6100627
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
Stewart, K. D., Matza, L. S., Chinthammit, C., Pavo, I. J., Bartee, A. K., & Boye, K. S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01907-y
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Fortin, S. M., Sanchez-Navarro, M. J., Hu, J., Zhou, M., Zhang, C., Petticord, M. C., Alonso, B., Cohen, S. A., & Hayes, M. R. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102427
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Yaseen, M., Ameer, A., Ali, Z., Jamali, J. A., Kumar, A., Siddiqui, M. B. A., Kumari, P., Hassaan, M., Nanwani, P., Basit, M. A., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005353
Cagrilintide–semaglutide: a new option for patients with type 2 diabetes
Scheen, A. J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00129-4
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 2
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Zhong, Y., Tan, X., Zhang, L., & Wu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1916932 · Cited by 1
Meng, Y., Jin, T., Ren, L., Thompson, M. L., & Wang, Y. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0033 · Cited by 1
Xu, R., Chang, Y., Su, E., Wang, Y., Zhang, Y., Ma, X., Han, X., & Zhu, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1853598
Krzystek, Ł., Buć, K., Buć, P., Mazurek, M., Józefczyk, J., Zieliński, K., Ganczar, K., Jurkowski, S., Rudzińska, M., & Zalewski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4388
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347782
Self-citationKhan, B. W., Agha, S. A., Qamar, I., Khattak, M. H., Rehman, A., Qazi, T. I., Siddiqui, S. A., Zeeshan, N., Khan, U. Z., Bibi, H., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05809-5
The Life‐Saving Benefit of the Living Donor Kidney Evaluation: A Mini Review
Holzner, M. L., Matas, A. J., Park, S., Langas, A., Hoffman, A. L., Heyne, N., Guthoff, M., Flechner, S. M., & Shapiro, R. (2025) · Clinical Transplantation · doi:10.1111/ctr.70253
Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss
Tysoe, O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01156-2 · Cited by 2
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Metadata
- Authors
- Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D.
- Affiliations
- University of Leicester (GB)
- Endocrine and Metabolic Research, LMC Healthcare, Brampton, ON, Canada
- Novo Nordisk (Denmark) (DK)
- University of Alabama at Birmingham (US)
- Diabetes Complications Research Centre, University College Dublin School of Medicine, Dublin
- The University of Texas Southwestern Medical Center (US)
- Velocity Clinical Research at Medical City, Dallas
- C-ENDO Diabetes and Endocrinology Clinic Calgary, Calgary, AB, Canada
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 648-659
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411522182
- Cited by
- 143
- References
- 28
- Citations by year
- 2026: 105 · 2025: 38
- FWCI
- 96.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cagrilintide, semaglutide, type 2 diabetes, obesity, overweight, weight loss, combination therapy, continuous glucose monitoring, HbA1c, gastrointestinal adverse effects, drug safety, lifestyle intervention, treatment policy estimand, weight management, drug repurposing, GLP-1 receptor agonists
- MeSH terms
- Continuous Glucose Monitoring, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Life Style, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Overweight, Glucagon-Like Peptide 1, Intention to Treat Analysis, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.